Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,646 JPY | +0.64% | +3.26% | -2.34% |
08:36am | Bayer plans to apply for approval of drug to treat menopausal symptoms | DP |
08:30am | Bayer to seek approval for menopausal relief drug after third trial win | RE |
Business Summary
Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Number of employees: 14,484
Sales per Business
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 1,296,163 | 100.0 % | 1,518,619 | 100.0 % | +17.16% |
Sales per region
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
43.0
%
| 537,452 | 41.5 % | 652,441 | 43.0 % | +21.40% |
Established Markets
23.6
%
| 315,162 | 24.3 % | 358,407 | 23.6 % | +13.72% |
Japan
17.3
%
| 258,758 | 20.0 % | 262,303 | 17.3 % | +1.37% |
International
9.5
%
| 110,081 | 8.5 % | 144,735 | 9.5 % | +31.48% |
Greater China
5.3
%
| 66,305 | 5.1 % | 80,011 | 5.3 % | +20.67% |
Other
1.4
%
| 8,406 | 0.6 % | 20,722 | 1.4 % | +146.51% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | Oct. 31 |
Kenji Yasukawa
CHM | Chairman | 63 | 86-03-31 |
Compliance Officer | - | 22-09-30 | |
Chief Tech/Sci/R&D Officer | - | - | |
Chief Tech/Sci/R&D Officer | - | - | |
Director/Board Member | 65 | 06-08-31 | |
Noriyuki Uematsu
BRD | Director/Board Member | 63 | 16-05-31 |
Hiroko Sakai
BRD | Director/Board Member | 63 | 83-03-31 |
Atsushi Kamide
IRO | Public Communications Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Takashi Tanaka
BRD | Director/Board Member | 67 | 21-05-31 |
Mamoru Sekiyama
BRD | Director/Board Member | 74 | 17-05-31 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Tatsuro Ishizuka
BRD | Director/Board Member | 68 | 19-05-31 |
Noriyuki Uematsu
BRD | Director/Board Member | 63 | 16-05-31 |
Eriko Sakurai
BRD | Director/Board Member | 63 | - |
Director/Board Member | 65 | 06-08-31 | |
Haruko Shibumura
BRD | Director/Board Member | 59 | 19-05-31 |
Hiroko Sakai
BRD | Director/Board Member | 63 | 83-03-31 |
Hiroo Sasaki
BRD | Director/Board Member | 68 | 18-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,809,663,075 | 1,788,385,938 ( 98.82 %) | 16,676,652 ( 0.9215 %) | 98.82 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
8,333,333 | 8.71% | 32,999,999 $ | |
7,266,342 | 3.89% | 22,961,641 $ | |
FIBROGEN, INC. 5.03% | 4,968,367 | 5.03% | 10,189,127 $ |
ASTELLAS PHARMA INC. 0.04% | 731,000 | 0.04% | 8,066,059 $ |
ONCOLYS BIOPHARMA INC. 3.59% | 727,200 | 3.59% | 2,837,476 $ |
Company contact information
Astellas Pharma, Inc.
2-5-1 Nihonbashi-Honcho Chuo-Ku
103-8411, Tokyo
+81 3 3244 3000
http://www.astellas.comGroup companies
Name | Category and Sector |
---|---|
Astellas BV
Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The private company is based in Leiden, Netherlands. |
Financial Conglomerates
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.34% | 19.66B | |
+30.83% | 687B | |
+30.84% | 595B | |
+0.01% | 378B | |
+15.18% | 316B | |
+11.39% | 308B | |
+0.11% | 211B | |
-6.50% | 208B | |
-3.92% | 203B | |
-3.72% | 157B |
- Stock
- Equities
- Stock Astellas Pharma Inc. - Japan Exchange
- Company Astellas Pharma Inc.